CoChat
Sign Up
Cited by 758Pharmacology and Obesity TreatmentBariatric Surgery and OutcomesEating Disorders and Behaviors

The DOI matches its Crossref record.

Executive Summary

Open access
·1998·Obesity Research
DOI 10.1002/j.1550-8528.1998.tb00690.x
Open this paper in CoChat — free accountOpen PDF

Abstract

As of September 1997, the Food and Drug Administration (FDA) requested the voluntary withdrawal from the market of dexfenfturarnine and fenfturamine due to a reported association between valvular disease and the use of dexfenfturamine or fenfturamine alone or combined with phentermine.The use of these drugs for weight reduction, therefore, is not recommended in this report.Sibutramine is approved by FDA for long-term use.It has limited but definite effects on weight loss and can facilitate weight loss maintenance.(Note: FDA approval for orlistat is pending a resolution of labeling issues and results of Phase III trials.)

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/j.1550-8528.1998.tb00690.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

Sorted by citations

Items 601–700 of 757

Related

See all

Metadata

Venue
Obesity Research
Publisher
Wiley
Published
1998-09
Volume
6
Issue
S2
ISSN
  • 1071-7323 (ISSN-L)
  • 1550-8528
DOI
10.1002/j.1550-8528.1998.tb00690.x
OpenAlex
W4246016694
Cited by
758
References
0
Citations by year
2026: 9 · 2025: 6 · 2024: 11 · 2023: 11 · 2022: 15 · 2021: 14 · 2020: 14 · 2019: 19 · 2018: 16 · 2017: 23 · 2016: 32 · 2015: 36 · 2014: 50 · 2013: 45 · 2012: 42
FWCI
10.98
Type
journal article
Language
en
Open access
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor, 5119 d)
Locations
Obesity Research (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Social Sciences › Psychology › Clinical Psychology › Eating Disorders and Behaviors
Keywords
dexfenfluramine, fenfluramine, valvular heart disease, phentermine, sibutramine, orlistat, weight loss, weight loss maintenance, obesity pharmacotherapy, drug safety

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review